




Healthcare Industry News: coated stent
News Release - January 4, 2007
French Court Rules in Favor of evYsio Medical Devices in Patent Litigation Against Abbott Laboratories
Xience(TM) V Drug-coated stent Now Under Injunction in FranceVANCOUVER, British Columbia--(HSMN NewsFeed)--evYsio Medical Devices ULC, a private Canadian company, announced that a French court has ruled in its favor in a patent infringement lawsuit it commenced against affiliates of Abbott Laboratories (NYSE:ABT ). In particular, the Tribunal de Grande Instance de Paris ruled that Abbott's Xience(TM) V drug-eluting coronary stent infringes evYsio's European Patent No. EP-B- 0 888 093 and has awarded evYsio the right to enjoin the importation, offering for sale, or sale of the Xience(TM) V stent in France. This injunction is now in effect. Abbott may appeal the decision.
evYsio and/or Medtronic, Inc. (NYSE:MDT ) have commenced infringement lawsuits in other countries alleging that Abbott's MULTI-LINK Vision® and/or Xience(TM) V coronary stents infringe patents under exclusive worldwide license to Medtronic from evYsio, including in the United States, Ireland, the United Kingdom, and Germany.
Background on evYsio
evYsio Medical Devices ULC is a private, Vancouver-based developer of vascular medical products. It develops lesion-specific stents and special medical devices for use in the fields of interventional cardiology, radiology and endovascular medicine.
Source: evYsio Medical Devices
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.